Published in Infect Immun on September 01, 2001
The role of infections in autoimmune disease. Clin Exp Immunol (2009) 1.47
Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol (2009) 1.43
Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol (2004) 1.26
Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol (2011) 1.17
Rheumatic Heart Disease: Molecules Involved in Valve Tissue Inflammation Leading to the Autoimmune Process and Anti-S. pyogenes Vaccine. Front Immunol (2013) 1.16
Immune evasion, immunopathology and the regulation of the immune system. Pathogens (2013) 0.94
B- and T-cell responses in group a streptococcus M-protein- or Peptide-induced experimental carditis. Infect Immun (2009) 0.94
Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem (2010) 0.92
Understanding rheumatic fever. Rheumatol Int (2011) 0.92
HLA class II DR and DQ genotypes and haplotypes associated with rheumatic fever among a clinically homogeneous patient population of Latvian children. Arthritis Res Ther (2007) 0.89
A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun (2002) 0.87
HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther (2003) 0.86
Rheumatic heart disease: 15 years of clinical and immunological follow-up. Vasc Health Risk Manag (2007) 0.84
Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol (2014) 0.83
Relevance of molecular mimicry in the mediation of infectious myocarditis. J Cardiovasc Transl Res (2013) 0.83
Identification of streptococcal m-protein cardiopathogenic epitopes in experimental autoimmune valvulitis. J Cardiovasc Transl Res (2013) 0.83
Rheumatic Fever. Images Paediatr Cardiol (2002) 0.81
Strategies in the development of vaccines to prevent infections with group A streptococcus. Hum Vaccin Immunother (2013) 0.80
The role of the gut microbiota in the pathogenesis of antiphospholipid syndrome. Curr Rheumatol Rep (2015) 0.76
Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. Infect Immun (2013) 0.75
Circulating level of regulatory T cells in rheumatic heart disease: An observational study. Indian Heart J (2016) 0.75
"HLA-G 3'UTR gene polymorphisms and rheumatic heart disease: a familial study among South Indian population". Pediatr Rheumatol Online J (2017) 0.75
HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens (1992) 6.87
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Defining criteria for autoimmune diseases (Witebsky's postulates revisited) Immunol Today (1993) 3.81
Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med (1985) 2.53
The complete amino acid sequence of a biologically active 197-residue fragment of M protein isolated from type 5 group A streptococci. J Biol Chem (1984) 2.40
Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today (1996) 1.81
Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol (1991) 1.75
Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation (1995) 1.36
Cellular reactivity studies to streptococcal antigens. Migration inhibition studies in patients with streptococcal infections and rheumatic fever. J Clin Invest (1974) 1.31
Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J Immunol (1989) 1.26
Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol (1994) 1.13
Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun (1997) 1.11
Identification of mononuclear cells and T cell subsets in rheumatic valvulitis. Clin Immunol Immunopathol (1989) 1.10
Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest (1986) 1.06
HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation (1999) 1.05
Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol (1989) 1.01
Immunoreactivity of anti-streptococcal monoclonal antibodies to human heart valves. Evidence for multiple cross-reactive epitopes. Am J Pathol (1991) 0.99
Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol (2000) 0.97
Lymphocyte growth from cardiac allograft biopsy specimens with no or minimal cellular infiltrates: association with subsequent rejection episode. J Heart Transplant (1989) 0.95
Tissue distribution of lymphocytes in rheumatic heart valves as defined by monoclonal anti-T cell antibodies. Am J Med (1983) 0.95
HLA-DR typing and lymphocyte subset evaluation in rheumatic heart disease: a search for immune response factors. Am Heart J (1986) 0.94
Rheumatic carditis: in vitro responses of peripheral blood leukocytes to heart and streptococcal antigens. Arthritis Rheum (1973) 0.90
Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Circulation (1991) 0.88
Preferential recognition of human myocardial antigens by T lymphocytes from rheumatic heart disease patients. Infect Immun (1997) 0.85
HLA class II antigens in rheumatic fever. Analysis of the DR locus by restriction fragment-length polymorphism and oligotyping. Hum Immunol (1994) 0.83
Antigenic specificity of lymphocytes isolated from valvular specimens of rheumatic fever patients. J Autoimmun (1995) 0.82
A genetic marker for rheumatic heart disease. Br Heart J (1987) 0.82
Antibodies in the sera of acute rheumatic fever patients bind to human cardiac tropomyosin. J Autoimmun (1997) 0.80
Lack of T cell response to cardiac myosin and a reduced response to PPD in patients with idiopathic dilated cardiomyopathy. J Autoimmun (1997) 0.79
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Comparison of the genomes of two Xanthomonas pathogens with differing host specificities. Nature (2002) 8.42
Amplification of a species-specific DNA fragment of Mycobacterium tuberculosis and its possible use in diagnosis. J Clin Microbiol (1991) 5.99
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Properties of proteins MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect Immun (1986) 3.80
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last? Parasitol Today (1996) 3.60
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med (1984) 3.49
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis (2007) 2.68
Immunological self, nonself discrimination. Science (1987) 2.59
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proc Natl Acad Sci U S A (1984) 2.52
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet (1996) 2.29
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J Immunol (1987) 2.27
A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature (1988) 2.26
MPB59, a widely cross-reacting protein of Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol (1986) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann Neurol (2001) 2.16
The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. Nephrol Dial Transplant (1998) 2.16
Endoscopic diagnosis and treatment of an esophageal bezoar resulting from bulk laxative ingestion. Endoscopy (1994) 2.14
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med (1998) 2.13
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) (2011) 2.00
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis. Am Heart J (2001) 1.97
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature (1987) 1.85
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol (2000) 1.84
Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity (1995) 1.83
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79
Chronic Lyme arthritis. Clinical and immunogenetic differentiation from rheumatoid arthritis. Ann Intern Med (1979) 1.79
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol (1993) 1.78
A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology (1999) 1.75
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest (2001) 1.72
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res (1998) 1.72
MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol (1992) 1.71
Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J Immunol (1996) 1.70
Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis (1997) 1.70
Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol (1993) 1.70
Multiprimer PCR system for differential identification of mycobacteria in clinical samples. J Clin Microbiol (1996) 1.68
Species-specific identification of Mycobacterium bovis by PCR. Microbiology (1995) 1.68
Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol (2001) 1.68
Testing an intervention to prevent further abuse to pregnant women. Res Nurs Health (1999) 1.67
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol (2001) 1.65
Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci U S A (2000) 1.65